Literature DB >> 33058298

Oral health-related quality of life in X-linked hypophosphataemia and osteogenesis imperfecta.

Hans Gjørup1, Signe Sparre Beck-Nielsen2, Jannie Dahl Hald3, Dorte Haubek4.   

Abstract

X-linked hypophosphataemia (XLH) and osteogenesis imperfecta (OI) are rare congenital disorders characterised by skeletal dysplasia. The two disorders may include dental anomalies potentially affecting individual well-being. The aims of study were (a) to assess the oral health-related quality of life (OHRQoL) in Danish adults with XLH or OI, and (b) to compare the results of the groups. A cross-sectional study including 35 adults with XLH, 56 adults with OI type I and 17 adults with OI types III-IV was conducted. The OHRQoL was assessed by the 49-item version of the questionnaire Oral Health Impact Profile (OHIP). Summed domain scores (seven) were compared between XLH and OI groups. Prevalence of severe impact on OHRQoL (scores 3-4) was compared between groups. The median scores in XLH group exceeded the medians in OI (P < .05) in the domains functional limitation (XLH:6.5; OI:4.0), pain (XLH:9.5; OI:5.0), psychological discomfort (XLH:5.5; OI:2.0), psychological disability (XLH:2.0; OI:0.0), handicap (XLH:2.0; OI:0.0) and total OHIP (XLH:35.0; OI:14.0). Differences in domains physical disability (XLH: 4.0; OI: 1.0) and social disability (XLH: 0.0; OI: 0.0) were not significant. Prevalence of severe impact on OHRQoL in the XLH group significantly exceeded the level in OI group in the domains functional limitation (XLH: 59%; OI: 35%), psychological discomfort (XLH: 38%; OI: 20%) and physical disability (XLH: 32%; OI: 13%). In conclusion, adults with XLH experience a higher negative impact on their OHRQoL than adults with OI. Only to a minor degree, individuals with OI types III-IV experience a higher impact on OHRQoL than individuals with OI type I.
© 2020 The Authors. Journal of Oral Rehabilitation published by John Wiley & Sons Ltd.

Entities:  

Keywords:  X-linked hypophosphataemia; disability; familial hypophosphataemic rickets; oral health; osteogenesis imperfecta; quality of life; tooth

Mesh:

Year:  2020        PMID: 33058298     DOI: 10.1111/joor.13114

Source DB:  PubMed          Journal:  J Oral Rehabil        ISSN: 0305-182X            Impact factor:   3.837


  4 in total

Review 1.  Interdisciplinary management of FGF23-related phosphate wasting syndromes: a Consensus Statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia.

Authors:  Andrea Trombetti; Nasser Al-Daghri; Maria Luisa Brandi; Jorge B Cannata-Andía; Etienne Cavalier; Manju Chandran; Catherine Chaussain; Lucia Cipullo; Cyrus Cooper; Dieter Haffner; Pol Harvengt; Nicholas C Harvey; Muhammad Kassim Javaid; Famida Jiwa; John A Kanis; Andrea Laslop; Michaël R Laurent; Agnès Linglart; Andréa Marques; Gabriel T Mindler; Salvatore Minisola; María Concepción Prieto Yerro; Mario Miguel Rosa; Lothar Seefried; Mila Vlaskovska; María Belén Zanchetta; René Rizzoli
Journal:  Nat Rev Endocrinol       Date:  2022-04-28       Impact factor: 43.330

2.  New 3D Cone Beam CT Imaging Parameters to Assist the Dentist in Treating Patients with Osteogenesis Imperfecta.

Authors:  Daniela Messineo; Valeria Luzzi; Francesca Pepe; Luca Celli; Arianna Turchetti; Anna Zambrano; Mauro Celli; Antonella Polimeni; Gaetano Ierardo
Journal:  Healthcare (Basel)       Date:  2020-12-10

Review 3.  Dental Implants in People with Osteogenesis Imperfecta: A Systematic Review.

Authors:  Ole Oelerich; Johannes Kleinheinz; Lauren Bohner; Vera Wiesmüller; Marcel Hanisch
Journal:  Int J Environ Res Public Health       Date:  2022-01-29       Impact factor: 3.390

4.  An Expert Perspective on Phosphate Dysregulation With a Focus on Chronic Hypophosphatemia.

Authors:  Fahad Aljuraibah; Justine Bacchetta; Maria Luisa Brandi; Pablo Florenzano; Muhammad K Javaid; Outimaija Mäkitie; Adalbert Raimann; Mariano Rodriguez; Heide Siggelkow; Dov Tiosano; Marc Vervloet; Carsten A Wagner
Journal:  J Bone Miner Res       Date:  2021-12-23       Impact factor: 6.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.